Friday, June 14, 2019
Regeneron releases positive data on REGN1979
Regeneron Pharmaceuticals (NASDAQ:REGN) announced positive early-stage data for REGN1979 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
REGN1979 is an investigational bispecific monoclonal antibody and is designed to trigger tumor killing by binding to both a B-cell tumor protein and an immune system T-cell receptor.
The company says the emerging data, which includes patients with R/R diffuse large B-cell lymphoma who had progressed after CAR-T therapy, will be presented at the European Hematology Association meeting.
REGN +0.19% after hours to $308.00.
ArQule gains after reporting blood cancer results
ArQule (NASDAQ:ARQL) +35.9% pre-market after releasing preliminary results from its phase 1 dose escalation study for ARQ 531 demonstrates substantial anti-tumor activity and a favorable safety profile.
Four of six evaluable CLL patients, all with the BTK-C481S mutation, from cohort 7 (65 mg) experienced a partial response, according to results delivered at the 2019 European Hematology Association meeting in Amsterdam.
ARQL says it is “now focused on finalizing the recommended phase 2 dose and planning for the expansion of our clinical efforts with ARQ 531 into later stage trials across multiple indications as a single agent and as a combination therapy.”
Alexandria RE leads development of opioid addiction care campus
Alexandria Real Estate Equities (NYSE:ARE), in partnership with Alphabet (NASDAQ:GOOG) company Verily, is designing and developing a campus in Dayton, OH, to support OneFifteen’s comprehensive model of care for opioid addiction.
The 59,000-square-foot campus on 4.3 acres will include dedicated facilities for rehabilitation, sober living, family reunification, and community transition.
The campus’s spaces for inpatient residential and outpatient clinical care will open this summer and the full campus is expected to be completed in 2020.
OneFifteen, formed earlier this year by Kettering Health Network, Premier Health (OTCPK:PHGRF), and Verily, is a non-profit ecosystem dedicated to the full and sustained recovery of people living with opioid addiction.
Bluebird’s new data for LentiGlobin for TDT
Bluebird (NASDAQ:BLUE) comments on long-term safety and efficacy data for LentiGlobin gene therapy for Transfusion-dependent β-Thalassemia.
In the Phase 1/2 Northstar study, patients with TDT who don’t have a β0/β0 genotype achieved up to 3.8 years of transfusion independence.
In the ongoing Phase 3 Northstar-2 study, four of five evaluable study patients (with TDT, without β0/β0 genotype) achieved transfusion independence.
Janssen Tremfya for psoriatic arthritis meets primary endpoints
Janssen Pharmaceutical’s Phase 3 DISCOVER 1 and 2 studies evaluating the safety and efficacy of guselkumab in adults with active moderate to severe psoriatic arthritis met their primary endpoints of American College of Rheumatology 20% improvement.
Safety profiles observed for guselkumab in the DISCOVER program were consistent with previous studies of guselkumab and Tremfya current prescribing information.
Johnson & Johnson’s (NYSE:JNJ) Janssen unit says the data from the studies will serve as the basis of submissions to the U.S. Food and Drug Administration and European Medicines Agency seeking approval for guselkumab as treatment for psoriatic arthritis, which are anticipated for later this year.
Subscribe to:
Posts (Atom)